Placeholder Banner

BIO Presents Dr. Ganesh Kishore New Award for Leadership and Legacy in Industrial Biotechnology

April 20, 2016

Washington, D.C. (April 20, 2016) The Biotechnology Innovation Organization (BIO) presented Dr. Ganesh Kishore, CEO, MLSCFI and co-Managing Partner, Spruce Capital Partners, the first annual BIO Leadership and Legacy Award today during BIO’s 13th Annual World Congress on Industrial Biotechnology. The new award was created to honor an individual who has shown exemplary leadership and who has dedicated a significant portion of their career to advancing industrial biotechnology and growing the biobased economy. The world’s largest industrial biotechnology event was held April 17-20, 2016 at the San Diego Convention Center in San Diego, CA.

“BIO is pleased to announce Dr. Ganesh Kishore as winner of the first annual BIO Leadership and Legacy Award in Industrial Biotechnology,” said Brent Erickson, executive vice president for BIO’s Industrial & Environmental Section. “The BIO Leadership and Legacy Award honors those who have left a lasting impression on the industry and whose legacy will endure the test of time. This award is dedicated to all who have left and continue to leave their mark in the field of industrial biotechnology.”

Dr. Kishore has a distinguished track record of accomplishments in industrial and agriculture biotechnology research and development and business.

He was a senior executive and innovation leader at Monsanto and DuPont. He has co-founded three successful entities since 2002, across the spectrum of industrial biosciences, agriculture, and environment.

In 2007, Dr. Kidhore left DuPont where he was Chief Biotechnology Officer to join Malaysian Life Science Capital Fund (MLSCF) as its CEO and later cofounded Spruce Capital Partners in 2013.

He serves on the board of three publicly listed entities, three privately held companies and the Advisory Board of Washington University. Dr. Kishore holds seventy issued patents and has sixty technical publications.

In 2015, Dr. Kishore was named to the WorldVIEW 100 list as one of the most influential people in biotech today.

All programs at the World Congress on Industrial Biotechnology were open to attendance by members of the media. Complimentary media registration was available to editors and reporters working full time for print, broadcast or web publications with valid press credentials.

For more information on the conference, please visit http://go.bio.org/WorldCongress2016.html. For assistance, please contact [email protected].

 

About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.

Upcoming BIO Events

 
BIO International Convention
June 6-9, 2016
San Francisco, CA
 
BIO Investor Forum
October 18-19, 2016
San Francisco, CA

 

Discover More
BIO President & CEO John F. Crowley released the following statement:“A healthy and prosperous society is vitally important to the American people and to the world. The public health, economic security and our national security are best served…
“The Biotechnology Innovation Organization (BIO) applauds today's announcement from the USDA's Animal and Plant Health Inspection Service (APHIS) expanding the scope of biotechnology exemptions for modified plants under 7 CFR part 340. This…
BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities."Manufacturers should have the choice to effectuate 340B pricing in the manner they deem most efficient…